ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
Dow Jones
42.063,36
0,09%
Euro vs US Dollar
1,11745
-0,01%
Bitcoin
63.062,58
-0,22%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Amarin Corp PLC (AMRN)

  7. Amarin Corp PLC (AMRN) News

AMRN

Amarin (AMRN)

Amarin Corp PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AMRN
DatumZeitQuelleÜberschriftSymbolFirma
09/09/202413h30GlobeNewswire Inc.Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual EuropeNASDAQ:AMRNAmarin Corp PLC
22/08/202414h30GlobeNewswire Inc.Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressNASDAQ:AMRNAmarin Corp PLC
05/08/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
01/08/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRNAmarin Corp PLC
31/07/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
31/07/202413h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRNAmarin Corp PLC
31/07/202413h00GlobeNewswire Inc.Amarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
29/07/202423h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
17/07/202422h15GlobeNewswire Inc.Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in PortugalNASDAQ:AMRNAmarin Corp PLC
17/07/202414h00GlobeNewswire Inc.Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024NASDAQ:AMRNAmarin Corp PLC
08/07/202413h30GlobeNewswire Inc.Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)NASDAQ:AMRNAmarin Corp PLC
04/06/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
04/06/202413h30GlobeNewswire Inc.Amarin Board of Directors Announces CEO TransitionNASDAQ:AMRNAmarin Corp PLC
28/05/202414h15GlobeNewswire Inc. Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.NASDAQ:AMRNAmarin Corp PLC
06/05/202414h00GlobeNewswire Inc.Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:AMRNAmarin Corp PLC
01/05/202413h00GlobeNewswire Inc. Amarin Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:AMRNAmarin Corp PLC
24/04/202420h00GlobeNewswire Inc.Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventNASDAQ:AMRNAmarin Corp PLC
22/04/202414h00GlobeNewswire Inc.Amarin Announces Results of Annual General Meeting of ShareholdersNASDAQ:AMRNAmarin Corp PLC
15/04/202414h00GlobeNewswire Inc.Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024NASDAQ:AMRNAmarin Corp PLC
08/04/202414h00GlobeNewswire Inc.Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24NASDAQ:AMRNAmarin Corp PLC
08/04/202412h30PR Newswire (Canada)New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
06/04/202421h30GlobeNewswire Inc.New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNASDAQ:AMRNAmarin Corp PLC
03/04/202414h00GlobeNewswire Inc.Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeNASDAQ:AMRNAmarin Corp PLC
25/03/202413h00GlobeNewswire Inc.Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoNASDAQ:AMRNAmarin Corp PLC
04/03/202423h30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AMRNAmarin Corp PLC
04/03/202414h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AMRNAmarin Corp PLC
29/02/202413h06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMRNAmarin Corp PLC
29/02/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRNAmarin Corp PLC
29/02/202413h00GlobeNewswire Inc.Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AMRNAmarin Corp PLC
 Showing the most relevant articles for your search:NASDAQ:AMRN

Kürzlich von Ihnen besucht

BIT
I08985
Intesa Sanpaolo
TSXV
OTGO.H
O2Gold
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten